// App-Quantinova.ai

: A phase 2 study of immunogenic cell death inducer PT-112 in patients with metastatic castration-resistant prostate cancer.

Researchers

Presenter

  • Alan Haruo Bryce

Principal Investigators

  • Daniel D. Karp

  • Scott T. Tagawa

  • Luke T. Nordquist

  • Dana E. Rathkopf

  • Nabil Adra

  • Tanya B. Dorff

  • Johan Baeck

  • Joseph Francis O'Donnell

  • Tyler David Ames

  • Christina Y. Yim

  • Matthew Price

  • Howard I. Scher

Medical Centers

  • Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN

  • Urology Cancer Center, Omaha, NE

  • Mayo Clinic, Phoenix, AZ

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Weill Cornell Medical College of Cornell University, New York, NY

  • City of Hope, Duarte, CA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Alkaline phosphatase

  • Circulating tumor cells

Drug/Treatment

  • Androgen Tear

  • taxane

  • PT112

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • II

Study Id's

  • NCT02266745

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved